Pacira BioSciences Stock Price and Value Analysis

Should you buy Pacira BioSciences stock? (NasdaqGS:PCRX). Let's see how it does in our automated value investing analysis system.

PCRX Free Cash Flow Trend

Free Cash Flow trendline for PCRX
Free Cash Flow trendline for Pacira BioSciences

Hmm, we can't give any reliable projection for Pacira BioSciences's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

  • This company is solid.
  • This company is not making money.
  • This stock looks overpriced.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the PCRX Numbers

PCRX Price
(Pacira BioSciences stock price per share)
PE Ratio versus Sector 919% higher than other Healthcare stocks
PE Ratio versus Industry 317% higher than other Drug Manufacturers - Specialty & Generic stocks
Cash Yield -0.05%
Free Cash Flow Jitter 36%

Is Pacira BioSciences Stock on Sale?

Based on our analysis, we believe that you should not buy Pacira BioSciences right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy PCRX Stock?

Does Pacira BioSciences have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.